GlassScriptPhysician profile
Melanie L Haney
NPI 1851437859
$13,484.74
in general payments reported to CMS, 2019-2025
29 companies · $3,447 in 2025
The $3,447 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,608 · 2022: $2,009 · 2023: $2,501 · 2024: $3,920 · 2025: $3,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,519 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Education: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,519.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Education | $548.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,821.90 | 2021-2025 | |
| Incyte Corporation | $1,700.61 | 2021-2025 | Opzelura, Zynyz, Jakafi |
| Regeneron Healthcare Solutions, INC. | $1,112.74 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,041.93 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,034.99 | 2021-2025 | |
| Janssen Biotech, INC. | $977.65 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $781.66 | 2021-2025 | Ilumya, Winlevi |
| Ucb, INC. | $704.80 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $663.66 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $620.53 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $616.50 | 2021-2025 | |
| Galderma Laboratories, L.P. | $563.54 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Leo Pharma INC. | $441.80 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $284.21 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $120.16 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Organon LLC | $113.35 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $104.07 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Mayne Pharma Commercial LLC | $89.93 | 2021-2025 | |
| Epi Health, LLC | $83.18 | 2021-2022 | |
| Pfizer INC. | $77.14 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $73.97 | 2021 | |
| Organogenesis INC. | $67.25 | 2025 | Via Matrix |
| Biofrontera INC. | $66.86 | 2022-2025 | Rhodoled Xl, Ameluz, Xepi |
| Kerecis Limited | $27.02 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Lnhc, INC | $24.72 | 2025 | Zelsuvmi |
| Almirall LLC | $24.25 | 2021 | |
| Cipher Pharmaceuticals US LLC | $22.32 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.